AiCure

Drug Sponsors

Hyperion to terminate DiaPep277 diabetes program after discovering serious misconduct by Andromeda employees

Tuesday, September 9, 2014 12:34 PM

Calling it “an unprecedented level of deceit,” Hyperion Therapeutics president and CEO Donald J. Santel told an analyst conference call the company is terminating its DiaPep277 development program for newly diagnosed type 1 diabetes.

More... »


AbbVie, Calico launch R&D collaboration for age-related diseases

Thursday, September 4, 2014 12:35 PM

Chicago-based AbbVie and Calico, a California-based Google-founded R&D company, have announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer.

More... »

CenterWatch

Johnson & Johnson to accelerate Ebola vaccine program in collaboration with NIH

Thursday, September 4, 2014 12:29 PM

Johnson & Johnson has committed to accelerate its Ebola vaccine program in collaboration with the NIH. J&J will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate to deliver immediate relief aid to address the current Ebola outbreak.

More... »

HHS contracts with Mapp Biopharmaceutical to develop ZMapp for Ebola

Thursday, September 4, 2014 12:22 PM

The development of a medication to treat illness from Ebola will be accelerated under a contract with the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR).

More... »

Exelixis cuts 70% of employees following failed pivotal trial

Wednesday, September 3, 2014 12:41 PM

Exelixis, a California-based biopharmaceutical company developing small molecule therapies for cancer, has announced top-line results from the final analysis of COMET-1, the phase III pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial did not meet its primary endpoint of demonstrating a statistically significant increase in overall survival (OS) for patients treated with cabozantinib as compared to prednisone.

More... »

Orgentec Diagnostika to acquire Corgenix

Friday, August 29, 2014 10:32 AM

Corgenix Medical, a Colorado-based, worldwide developer and marketer of diagnostic test kits, has agreed to be acquired by Orgentec Diagnostika, a specialty diagnostics company headquartered in Mainz, Germany. The strategic acquisition will extend both companies’ global distribution networks and broaden their portfoliod of specialty diagnostic assays.

More... »

Report: Pharma crosses new frontiers with global tiered pricing strategies

Wednesday, August 27, 2014 01:15 PM

Despite the adoption of tiered pricing strategies by pharmaceutical companies around the world, there is only a tenuous correlation between the prices of pharmaceutical products and the local economic conditions of the countries where they are launched, according to a comprehensive new study by IHS, a global source of critical information and insight, headquartered in Englewood, Colo.

More... »

Cilag International acquires Covagen

Wednesday, August 27, 2014 01:13 PM

Cilag International, a Switzerland-based affiliate of Janssen Pharmaceutical, a division of Johnson & Johnson, has acquired Covagen, a privately held biopharmaceutical company specializing in the development of multi-specific protein therapeutics through the FynomAb technology platform.

More... »

Medtronic acquires Sapiens Steering Brain Stimulation

Wednesday, August 27, 2014 01:12 PM

Medtronic, a Minneapolis, Minn., medical technology provider, has acquired Sapiens Steering Brain Stimulation (Sapiens SBS), a Netherlands-based, privately held developer of deep brain stimulation (DBS) technologies, for approximately $200 million in cash.

More... »

Covidien acquires Reverse Medical

Monday, August 25, 2014 02:11 PM

Covidien, a Dublin, Ireland-based global healthcare products company and manufacturer of medical devices and supplies, has acquired California-based Reverse Medical, a privately held medical device company focused on expanding the management of vascular disease. Financial terms of the transaction have not been disclosed.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs